Table 4.
PD-L1 positivity in tumor cells and tumor-infiltrating immune cells of different salivary gland carcinomas (n = 167).
| PD-L1 positivity in | ||
|---|---|---|
| tumor cells | tumor-infiltrating immune cells | |
| Mucoepidermoid carcinoma (n = 36) | 9 (25%) | 13 (36%) |
| Adenoic cystic carcinoma (n = 36) | 3 (8%) | 1 (3%) |
| Acinic cell carcinoma (n = 30) | 4 (13%) | 6 (20%) |
| Adenocarcinoma NOS (n = 12) | 2 (17%) | 4 (33%) |
| Epithelial-myoepithelial carcinoma (n = 11) | 0 | 2 (2%) |
| Salivary duct carcinoma (n = 10) | 3 (30%) | 4 (40%) |
| Carcinoma ex pleomorphic adenoma (n = 10) | 1 (10%) | 0 |
| Polymorphous low grade adenocarcinoma (n = 7) | 1 (14%) | 0 |
| Basal cell adenocarcinoma (n = 3) | 1 (33%) | 0 |
| Squamous cell carcinoma (n = 2) | 1 (50%) | 1 (50%) |
| Small cell carcinoma (n = 2) | 1 (50%) | 1 (50%) |
| Large cell carcinoma (n = 1) | 1 (100%) | 1 (100%) |
| Lymphoepithelial carcinoma (n = 1) | 1 (100%) | 1 (100%) |
| All carcinomas (n = 167) | 28 (17%) | 34 (20%) |
Patients with oncocytic carcinoma (n = 2), myoepithelial carcinoma (n = 2), cystadenocarcinoma (n = 1) and carcinosarcoma (n = 1) did not show any PD-L1 positivity in either tumor cells or tumor-infiltrating immune cells.